Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06967727 · ClinicalTrials.gov registry record
Registry and Natural History of Epilepsy-Dyskinesia Syndromes
A clinical trial of Epilepsy and Neurologic Disorder, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- 700
- Enrollment target
- 1
- Study location
NCT06967727: Recruiting study of Epilepsy and Neurologic Disorder, sponsored by Boston Children's Hospital.
NCT06967727 is a study of Epilepsy and Neurologic Disorder that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 700 participants, below the 948-participant average among 160 other Epilepsy trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06967727, a study of Epilepsy and Neurologic Disorder, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- 700 participants
- Enrollment target
- 1
- Study location
Study Summary
The Registry and Natural History of Epilepsy-Dyskinesia Syndromes is focused on gathering longitudinal clinical data as well as biological samples (blood, urine, and/or skin/tissue) from male and female patients, of all ages, who have a genetic diagnosis of epilepsy-dyskinesia syndromes. Through prospective review and molecular data analysis, the study aims to identify patterns and correlations between movement and seizure disorders, uncovering genotype-phenotype relationships. The initiative's goals are to enhance understanding of epilepsy-dyskinesia syndromes, inform precision medicine approaches, and foster international collaboration.
Primary Outcome
Establish a biobank for patients with epilepsy-dyskinesia syndromes, enabling quantitative profiling of biochemical biomarkers.
Conditions Studied
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2025-06-01 |
| Est. Completion | 2030-07 |
What NCT06967727 shows while recruiting
NCT06967727 is an observational study that tracks outcomes without assigning an intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, below the 948-participant average among 160 other Epilepsy trials with a reported enrollment target (26% lower).
The record links to 10 conditions, with Epilepsy appearing as the primary indexed condition, and to 0 interventions.
NCT06967727 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06967727 about?
NCT06967727 is a clinical study titled "Registry and Natural History of Epilepsy-Dyskinesia Syndromes". The Registry and Natural History of Epilepsy-Dyskinesia Syndromes is focused on gathering longitudinal clinical data as well as biological samples (blood, urine, and/or skin/tissue) from male and female patients, of all ages, who have a genetic diagnosis of epilepsy-dyskinesia syndromes. Through pro...
What is the current status of trial NCT06967727?
This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2025-06-01. Estimated completion is 2030-07.
What conditions does trial NCT06967727 study?
This clinical trial studies the following conditions: Epilepsy, Neurologic Disorder, Epilepsy in Children, Dyskinesias, Dyskinesia.
Who is sponsoring clinical trial NCT06967727?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06967727 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06967727's enrollment target sits among peer trials
700 9th of 160 higher than 151 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
RECRUITING
-
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
RECRUITING
-
SeizEAR Safety Study
RECRUITING · NA
-
Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
RECRUITING
-
Tumor Related Epilepsy
RECRUITING
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
- NCT02576483 · 700 participants
An Evaluation of LASIK, SMILE and PRK Surgery in Physicians
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI